S. Emanuel

发表

The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.

S. Emanuel, C. Rugg, R. H. Gruninger, 2005, Cancer research.

The discovery of macrocyclic XIAP antagonists from a DNA-programmed chemistry library, and their optimization to give lead compounds with in vivo antitumor activity.

Shana L. Posy, J. Fargnoli, R. Talbott, 2015, Journal of medicinal chemistry.

3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.

S. Emanuel, R. H. Gruninger, R. Lin, 2005, Bioorganic & medicinal chemistry letters.

Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.

Mary Adams, Niranjan Pandey, Terry V Hughes, 2008, Bioorganic & medicinal chemistry letters.

Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1).

S. Emanuel, R. H. Gruninger, Angel R. Fuentes-Pesquera, 2007, Bioorganic & medicinal chemistry letters.

Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.

S. Emanuel, P. Connolly, L. Jolliffe, 2003, Journal of medicinal chemistry.

Synthesis of 3-(1H-benzimidazol-2-yl)-5-isoquinolin-4-ylpyrazolo[1,2-b]pyridine, a potent cyclin dependent kinase 1 (CDK1) inhibitor.

S. Emanuel, R. Lin, P. Connolly, 2007, Bioorganic & medicinal chemistry letters.

Methode permettant de detecter des modulateurs du domaine kinase du recepteur du vegf

S. Emanuel, Dana L. Johnson, 2001 .

Discovery of tetrahydroisoquinoline-based bivalent heterodimeric IAP antagonists.

Shana L. Posy, R. Talbott, S. Emanuel, 2014, Bioorganic & medicinal chemistry letters.

Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity.

J. Fargnoli, R. Talbott, S. Emanuel, 2015, Journal of medicinal chemistry.

Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621.

S. Emanuel, R. Lin, P. Connolly, 2006, Bioorganic & medicinal chemistry letters.

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2

P. Ross-Macdonald, K. McIntyre, G. Trainor, 2012, Leukemia.

Discovery of anticancer agents of diverse natural origin

A. Kinghorn, D. Jarjoura, S. Emanuel, 2009, Pure and applied chemistry. Chimie pure et appliquee.

1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.

S. Emanuel, C. Rugg, R. H. Gruninger, 2005, Journal of medicinal chemistry.

Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.

S. Emanuel, R. H. Gruninger, Angel R. Fuentes-Pesquera, 2005, Journal of medicinal chemistry.

Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.

S. Emanuel, R. H. Gruninger, Angel R. Fuentes-Pesquera, 2005, Journal of medicinal chemistry.

Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.

S. Emanuel, R. H. Gruninger, R. Lin, 2007, Bioorganic & medicinal chemistry letters.

Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors.

S. Emanuel, R. Lin, Angel R. Fuentes-Pesquera, 2007, Bioorganic & medicinal chemistry letters.

(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.

Jian Li, Judith Baker, Hong-tao Lu, 2005, Journal of medicinal chemistry.

4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation.

S. Emanuel, R. H. Gruninger, R. Lin, 2007, Bioorganic & medicinal chemistry letters.

Synthesis and biological study of 4-aminopyrimidine-5-carboxaldehyde oximes as antiproliferative VEGFR-2 inhibitors.

S. Emanuel, P. Connolly, Shenlin Huang, 2006, Bioorganic & medicinal chemistry letters.

Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors.

Xin Chen, Yan Zhang, S. Emanuel, 2005, Journal of medicinal chemistry.

A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: design, synthesis, and biological activity.

S. Emanuel, P. Connolly, S. K. Wetter, 2008, Bioorganic & medicinal chemistry letters.

4 Development of High- Throughput Screening Assays in Scintillating Microplates (FlashPlates) to Identify Inhibitors of Kinase Activity

S. Emanuel, Stuart Emanuel, 2006 .

Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor

A. Calcagno, S. Ambudkar, S. Emanuel, 2006, Molecular Cancer Therapeutics.

A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models

M. Batchelor, G. Bignan, M. D'Andrea, 2004, Molecular Pharmacology.

Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families

J. Fargnoli, Derek J. Norris, J. Hunt, 2011, Clinical Cancer Research.

Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.

S. Emanuel, H. Ye, C. Derian, 2003, Bioorganic & medicinal chemistry letters.

Structures of adnectin/protein complexes reveal an expanded binding footprint.

Martin C. Wright, S. Sheriff, P. Morin, 2012, Structure.

A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor

Martin C. Wright, A. Yamniuk, M. Doyle, 2011, mAbs.

Protection against glutamate toxicity through inhibition of the p44/42 mitogen-activated protein kinase pathway in neuronally differentiated P19 cells.

R. Zivin, S. Emanuel, M. McMillian, 2001, Biochemical pharmacology.

Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors

Mary Adams, Niranjan Pandey, Terry V Hughes, 2008, Molecular Pharmacology.

Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors.

S. Emanuel, P. Connolly, S. Middleton, 2006, Bioorganic & medicinal chemistry letters.

Development of a Carbon-14 Labeling Approach to Support Disposition Studies with a Pegylated Biologic

A. D. Rodrigues, P. Morin, S. Emanuel, 2012, Drug Metabolism and Disposition.

7-[1H-Indol-2-yl]-2,3-dihydro-isoindol-1-ones as dual Aurora-A/VEGF-R2 kinase inhibitors: design, synthesis, and biological activity.

S. Emanuel, C. Rugg, Angel R. Fuentes-Pesquera, 2008, Bioorganic & medicinal chemistry letters.